CN118001423A - 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用 - Google Patents

亲水性抗Nectin-4抗体偶联药物及其制备方法和应用 Download PDF

Info

Publication number
CN118001423A
CN118001423A CN202410051888.5A CN202410051888A CN118001423A CN 118001423 A CN118001423 A CN 118001423A CN 202410051888 A CN202410051888 A CN 202410051888A CN 118001423 A CN118001423 A CN 118001423A
Authority
CN
China
Prior art keywords
mmol
gly
added
compound
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410051888.5A
Other languages
English (en)
Chinese (zh)
Inventor
黄云生
陆遥
盛国荣
汪小蓓
李德亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Aikerisi Biomedical Co ltd
Original Assignee
Hangzhou Aikerisi Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Aikerisi Biomedical Co ltd filed Critical Hangzhou Aikerisi Biomedical Co ltd
Priority to CN202410051888.5A priority Critical patent/CN118001423A/zh
Publication of CN118001423A publication Critical patent/CN118001423A/zh
Priority to PCT/CN2025/071654 priority patent/WO2025149013A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
CN202410051888.5A 2024-01-12 2024-01-12 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用 Pending CN118001423A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410051888.5A CN118001423A (zh) 2024-01-12 2024-01-12 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用
PCT/CN2025/071654 WO2025149013A1 (fr) 2024-01-12 2025-01-10 Conjugué anticorps anti-nectine 4 hydrophile-médicament, son procédé de préparation et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410051888.5A CN118001423A (zh) 2024-01-12 2024-01-12 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN118001423A true CN118001423A (zh) 2024-05-10

Family

ID=90946452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410051888.5A Pending CN118001423A (zh) 2024-01-12 2024-01-12 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN118001423A (fr)
WO (1) WO2025149013A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149013A1 (fr) * 2024-01-12 2025-07-17 杭州爱科瑞思生物医药有限公司 Conjugué anticorps anti-nectine 4 hydrophile-médicament, son procédé de préparation et son utilisation
WO2026037321A1 (fr) * 2024-08-13 2026-02-19 Lepu Biopharma Co., Ltd. Composés, compositions et méthodes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302649A (zh) * 2021-04-26 2023-01-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途
CN116726192B (zh) * 2022-12-29 2025-11-07 杭州爱科瑞思生物医药有限公司 N-烷氧烷基取代的喜树碱衍生物的抗体偶联药物
CN116870187A (zh) * 2022-12-29 2023-10-13 杭州爱科瑞思生物医药有限公司 N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物
CN116712562A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物
CN116712563A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-卤代烷基取代的喜树碱衍生物的抗体偶联药物
CN116712561A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 含n-亚甲基酰胺连接子的抗体-药物偶联物
CN118001423A (zh) * 2024-01-12 2024-05-10 杭州爱科瑞思生物医药有限公司 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149013A1 (fr) * 2024-01-12 2025-07-17 杭州爱科瑞思生物医药有限公司 Conjugué anticorps anti-nectine 4 hydrophile-médicament, son procédé de préparation et son utilisation
WO2026037321A1 (fr) * 2024-08-13 2026-02-19 Lepu Biopharma Co., Ltd. Composés, compositions et méthodes

Also Published As

Publication number Publication date
WO2025149013A1 (fr) 2025-07-17

Similar Documents

Publication Publication Date Title
CN111225896B (zh) 免疫调节剂化合物
CN111225665B (zh) 大环免疫调节剂
JP6921101B2 (ja) プロテインキナーゼ阻害剤及びその調製方法と医薬用途
CN102821602B (zh) 脂肪酸富马酸酯衍生物及其用途
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN116249683A (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
CA3017020A1 (fr) Agents antiviraux contre l'hepatite b
JP2022536845A (ja) Ｐｄ－ｌ１疾患の治療のための化合物
CN108699078A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
JP2022521746A (ja) グルタルイミド骨格に基づく硫黄含有化合物及びその応用
CN118001423A (zh) 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用
JP2021513996A (ja) Ｐｄ−ｌ１アンタゴニストとしてのインダン−アミン
CN113582980A (zh) 基于杂环和戊二酰亚胺骨架的化合物及其应用
JP7538803B6 (ja) イミダゾキノリンアミン誘導体、医薬組成物、その使用
WO2023141852A1 (fr) Inhibiteurs de la cdk2, leur procédé de préparation et leur utilisation
CN116375707A (zh) Menin抑制剂及其用途
CN114616234B (zh) 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
CA2967694A1 (fr) Derives indoliques et azaindoliques et leur utilisation dans le traitement de maladies neurodegeneratives
CN108864132A (zh) 一类冬凌草甲素衍生物及其制备方法和用途
WO2025149012A1 (fr) Dérivé de dolastatine, son procédé de préparation et son utilisation
WO2025067394A1 (fr) Dérivé d'amide d'exatécan substitué par halogène, son procédé de préparation et son utilisation
WO2019091046A1 (fr) Procédé de préparation d'un dérivé de lénalidomide et application associée
WO2019184919A1 (fr) Composé contenant de l'adamantane et son utilisation dans le traitement du cancer
CN110903289B (zh) 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination